PMID: 7515649Jan 1, 1994Paper

Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Eva KimbyE Löfvenberg

Abstract

Two hundred fifty-nine previously untreated patients with low-grade non-Hodgkin's lymphomas (NHLs), Ann Arbor stages III and IV, entered a randomized multicenter trial comparing the therapeutic effect of chlorambucil/prednisone (ChP) vs. CHOP. All patients had symptomatic disease. The therapeutic aim was to achieve an asymptomatic state in the ChP group (n = 132), while in CHOP-treated patients (n = 127) the intention was to reach a complete remission (CR). The response rate (CR+PR at 8 months) was 36% in the ChP and 60% in the CHOP group (p < 0.01). Three and 5-year survival rates were 59% and 41% in the ChP group and 64% and 44% in the CHOP group. The corresponding median survival times were 46 and 52 months. After correction for intercurrent deaths, the overall 5-year survival was 49% for ChP and 54% for CHOP-treated patients. The differences were statistically not significant. The time from diagnosis to randomization (time with asymptomatic disease) was longer than one year in half of the patients. The median survival time from diagnosis was 68 months, with no differences between the treatment groups. In all histological subgroups (CLL, IC, CC, and CB-CC), a higher remission rate was seen with the CHOP regimen but with no s...Continue Reading

Citations

Jun 1, 1996·Medical Oncology·V HjalmarE Kimby
Jan 20, 2007·Journal of Cancer Research and Clinical Oncology·Hege Vangstein AamotSverre Heim
Dec 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·W Hiddemann
Dec 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B Coiffier
Oct 22, 2003·Otolaryngologic Clinics of North America·Laxmeesh M Nayak, Daniel G Deschler
Jan 1, 1997·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·E J Sawyer, A R Timothy
Apr 1, 1997·International Journal of Radiation Oncology, Biology, Physics·J F De Los SantosJ W Lynch
Jun 23, 2000·Critical Reviews in Oncology/hematology·P SoubeyranH Eghbali
Sep 10, 2003·Seminars in Cancer Biology·Carsten HirtGottfried Dölken
Jan 1, 2010·Clinical & Developmental Immunology·Giulia MottaAlessio Nencioni
Feb 28, 2007·Leukemia & Lymphoma·Koen van Besien, Harry Schouten
Oct 11, 2007·Leukemia & Lymphoma·Christos Emmanouilides
May 9, 2001·Leukemia & Lymphoma·A TinmouthK R Imrie
Jan 4, 2012·British Journal of Haematology·Christopher McNamaraUNKNOWN British Society for Haematology Committee
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R L M HaasH Bartelink
Mar 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoMaura Brugiatelli
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emmanuel BachyGilles Salles
Jul 9, 2013·The Cochrane Database of Systematic Reviews·Gilad ItchakiMical Paul
Mar 7, 2009·Hematological Oncology·R L M Haas
Mar 17, 2010·Veterinary and Comparative Oncology·D M VailUNKNOWN Veterinary Cooperative Oncology Group
Mar 10, 2010·Drugs & Aging·Paolo F CaimiHillard M Lazarus
Aug 29, 2009·PharmacoEconomics·Talia FosterMason W Russell
Aug 9, 2008·The New England Journal of Medicine·Bruce D Cheson, John P Leonard
Sep 21, 2011·Expert Review of Anticancer Therapy·Samantha Jaglowski, Jeffrey A Jones
Jun 18, 2002·The Oncologist·Peter McLaughlin
Jul 10, 1999·Current Opinion in Hematology·R G Bociek, J O Armitage
Mar 13, 2013·Expert Review of Anticancer Therapy·Zhi-Ming LiAlden A Moccia

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved